[HTML][HTML] Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine …
HM Kantarjian, XG Thomas, A Dmoszynska… - Journal of clinical …, 2012 - ncbi.nlm.nih.gov
HM Kantarjian, XG Thomas, A Dmoszynska, A Wierzbowska, G Mazur, J Mayer, JP Gau…
Journal of clinical oncology, 2012•ncbi.nlm.nih.govMulticenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice,
With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of
Older Patients With Newly Diagnosed Acute Myeloid Leukemia - PMC Back to Top Skip to
main content NIH NLM Logo Access keys NCBI Homepage MyNCBI Homepage Main Content
Main Navigation Search PMC Full-Text Archive Search in PMC Advanced Search User
Guide Journal List J Clin Oncol PMC4874148 Other Formats PubReader PDF (183K) Actions …
With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of
Older Patients With Newly Diagnosed Acute Myeloid Leukemia - PMC Back to Top Skip to
main content NIH NLM Logo Access keys NCBI Homepage MyNCBI Homepage Main Content
Main Navigation Search PMC Full-Text Archive Search in PMC Advanced Search User
Guide Journal List J Clin Oncol PMC4874148 Other Formats PubReader PDF (183K) Actions …
Abstract
Purpose
This multicenter, randomized, open-label, phase III trial compared the efficacy and safety of decitabine with treatment choice (TC) in older patients with newly diagnosed acute myeloid leukemia (AML) and poor-or intermediate-risk cytogenetics.
ncbi.nlm.nih.gov